Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on The Middle East Health Journal.
Press releases published on July 7, 2025
Autonomix Medical, Inc. Announces Release of the Next CEO Corner Segment
GlobeNewswire
·
July 7, 2025
THE WOODLANDS, TX, July 07, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced the next CEO Corner segment has …
Conduit Pharmaceuticals Files New Patents Following AI-Driven Combination Discoveries
GlobeNewswire
·
July 7, 2025
Includes Conduit’s first composition of matter patent filing for AZD5658 and multiple new combination filings for AZD1656 and AZD5658 Patents derived from AI-led analysis conducted in partnership with Sarborg Limited NAPLES, Fla. and CAMBRIDGE, United …
Silo Pharma Advances PTSD Drug SPC-15 Toward Planned 2025 IND Submission with Pre-Clinical Study Data Expected in Q3 2025
GlobeNewswire
·
July 7, 2025
Planned submission of IND application in 2025; Phase 1 clinical trial to follow if IND application approved No new PTSD drug approvals in the U.S. in nearly 25 years; large potential addressable market for SPC-15 worldwide SARASOTA, FL, July 07, 2025 ( …
Medical Supplierz Expands Global Access to Leading Medical Manufacturers
EIN Presswire
·
July 7, 2025
KUWAIT, KUWAIT, July 7, 2025 /EINPresswire.com/ -- Medical Supplierz, a digital B2B procurement platform, has launched new initiatives to strengthen global connectivity between verified healthcare buyers and trusted medical manufacturers. The platform …
Allarity Therapeutics Announces Appointment of Jeff Ervin as Chief Financial Officer
GlobeNewswire
·
July 7, 2025
TARPON SPRINGS, Fla., July 7, 2025 -- Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated, dual PARP and WNT pathway inhibitor—as …
Inspire Medical Systems, Inc. to Report Second Quarter 2025 Financial Results on August 4, 2025
GlobeNewswire
·
July 7, 2025
MINNEAPOLIS, July 07, 2025 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire) will release financial results for the second quarter 2025 after the close of trading on Monday, August 4. Inspire’s management team will host a …
Collegium Announces $150 Million Share Repurchase Program
GlobeNewswire
·
July 7, 2025
STOUGHTON, Mass., July 07, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced its Board …
JenaValve's Trilogy™ THV System Procedures Live Broadcast at New York Valves 2025
GlobeNewswire
·
July 7, 2025
IRVINE, Calif., July 07, 2025 (GLOBE NEWSWIRE) -- JenaValve Technology, Inc., developer and manufacturer of the Trilogy™ Transcatheter Heart Valve (THV) System, today announced highlights from the New York Valves 2025 conference, with two live case …
Novel Digital Test Provides Revolutionary Tool to Assess Brain Chemistry
GlobeNewswire
·
July 7, 2025
SAN FRANCISCO, July 07, 2025 (GLOBE NEWSWIRE) -- For the first time, a study shows a digital assessment can provide a scientific measure of acetylcholine – a key brain chemical whose decline signals the progression of cognitive impairment and Alzheimer’s …
Chugai and Gero Enter into Joint Research and License Agreement to Develop Novel Therapies for Age-Related Diseases
GlobeNewswire
·
July 7, 2025
Collaboration to create novel antibody drug candidates using Chugai's proprietary antibody engineering technologies for drug targets identified through Gero's AI-driven human data-first platform Accelerating the creation of innovation by combining Gero's …
LENZ Therapeutics and Laboratoires Théa Announce Exclusive License and Commercialization Agreement for LNZ100 in Canada
GlobeNewswire
·
July 7, 2025
SAN DIEGO and CLERMONT-FERRAND, France, July 07, 2025 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ) and Laboratoires Théa (“Théa”) announced an exclusive license and commercialization agreement for Théa to register and commercialize LNZ100 for …
Catheter Precision, Inc. Announces First Purchase Order From University Hospital in Rennes, France
GlobeNewswire
·
July 7, 2025
FORT MILL, S.C., July 07, 2025 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (VTAK - NYSE/American), a US based medical device company focused on developing technologically advanced products for the cardiac electrophysiology market announced today that it …
UroGen Announces Completion of Enrollment in the Phase 3 UTOPIA Clinical Trial of UGN-103 for the Treatment of Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer
GlobeNewswire
·
July 7, 2025
PRINCETON, N.J., July 07, 2025 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it has completed …
Extendicare Announces Timing of 2025 Second Quarter Results and Conference Call
GlobeNewswire
·
July 7, 2025
MARKHAM, Ontario, July 07, 2025 (GLOBE NEWSWIRE) -- Extendicare Inc. (“Extendicare” or the “Company”) (TSX: EXE) announced today that it plans to release its financial results for the second quarter of 2025 after market close on Wednesday, August 6, 2025. …
KALA BIO to Host Virtual Key Opinion Leader (KOL) Event to Discuss the Potential of KPI-012 for the Treatment of Persistent Corneal Epithelial Defect (PCED)
GlobeNewswire
·
July 7, 2025
ARLINGTON, Mass., July 07, 2025 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye, today …
Denali Therapeutics Announces FDA Acceptance and Priority Review of Biologics License Application (BLA) for Tividenofusp Alfa for Hunter Syndrome (MPS II)
GlobeNewswire
·
July 7, 2025
FDA assigns PDUFA target action date of January 5, 2026, for decision on accelerated approval Tividenofusp alfa is designed to deliver missing enzyme to entire body and cross blood-brain barrier into the brain Tividenofusp alfa leads company’s broader …
Artelo Biosciences Announces Positive Preclinical Efficacy with ART12.11 in Stress-Induced Depression Model
GlobeNewswire
·
July 7, 2025
ART12.11, the Patented CBD:TMP Cocrystal, Demonstrates Potent Antidepressant-Like Activity and Cognitive Benefits Over Leading SSRI Data Being Presented at the 35th Annual International Cannabinoid Research Society Symposium SOLANA BEACH, Calif., July 07, …
Medicines for Poland Announces: Without pharmaceutical factories Europe will lose any war
GlobeNewswire
·
July 7, 2025
BRUSSELS, July 07, 2025 (GLOBE NEWSWIRE) -- The need to establish a fund under the EU budget to support the production of critical medicines in Europe is a conclusion drawn from an analysis of the impact of the war on the availability of medicines in …
Jasper Therapeutics Reports Clinical Data Update from Briquilimab Studies in Chronic Spontaneous Urticaria
GlobeNewswire
·
July 7, 2025
8 of 9 participants (89%) treated in the 240mg and 360mg single dose cohorts achieved a complete response 8 of 11 participants (73%) enrolled in the 180mg Q8W open label extension study achieved a complete response at 12 weeks Results from the 240mg Q8W …
Onco360 Has Been Selected as a National Specialty Pharmacy for Augtyro™ (repotrectinib)
GlobeNewswire
·
July 7, 2025
LOUISVILLE, Ky., July 07, 2025 (GLOBE NEWSWIRE) -- Onco360®, the nation’s leading independent specialty pharmacy, has added Augtyro™ (repotrectinib) manufactured by Bristol Myers Squibb to its comprehensive list of limited distribution therapies. Augtyro …